SSTR2 Inhibitors
5 drugsAbout SSTR2
SSTR2 (somatostatin receptor 2) is a GPCR that inhibits hormone secretion, cell proliferation, and neurotransmission. It is a member of the somatostatin receptor family and regulates diverse physiological processes via downstream signaling pathways.
SSTR2 is a therapeutic target with moderate genetic support, including associations with pneumonitis (score 0.51) and smoking initiation (score 0.51). Strong eQTL/pQTL signals (max H4: 0.99) further support SSTR2's role in disease.
SSTR2 is targeted by 5 FDA-approved small molecule drugs, including SIGNIFOR, LUTATHERA, DETECTNET, PALSONIFY, and NETSPOT, all approved for other indications. Four companies have approved SSTR2-targeting drugs, including RECORDATI RARE and AAA USA INC.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Pancreatic Neoplasm with only 1 trials.
- phase2 represents biological uncertainty with 53% completion.
SSTR2 Genetic Evidence Moderate
Genetic evidence provides moderate support for SSTR2 as a drug target.
Further investigation of SSTR2's role in pneumonitis and smoking initiation may reveal novel therapeutic opportunities.
Evidence Across Diseases
4 totalGWAS and other genetic studies link SSTR2 to 4 diseases.
🔗 Colocalization Evidence 3 strong
max H4: 0.99eQTL/pQTL signals for SSTR2 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top SSTR2 Drugs
Four companies have approved SSTR2-targeting drugs.
The presence of established players suggests a moderately competitive market with potential entry barriers.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| LUTATHERA | AAA USA INC | 2018 | 1 |
| DETECTNET | CURIUM | 2020 | 1 |
SSTR2 Drug Modality Landscape
Modalities
Routes of Administration
SSTR2 is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could differentiate new SSTR2-targeting therapies.
SSTR2 Clinical Trials 89 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 20 | 9 | 4 | 7 | 69% |
| Phase 2 | 50 | 18 | 14 | 18 | 56% |
| Phase 3 | 12 | 8 | 0 | 4 | 100% |
| Phase 4 | 7 | 4 | 1 | 2 | 80% |
Top Sponsors
By Modality
Top Conditions
SSTR2 Drug Approval Timeline (2012 - 2025)
The first SSTR2-targeting drug was approved in 2012, with the most recent in 2025.
The continued approval of SSTR2-targeting drugs suggests ongoing therapeutic interest and market potential.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 4 companies competing
- • Market share by company
Full Drug Portfolio
- • All 5 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 5-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 76 clinical trials targeting SSTR2.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities